Presentation (CTI)

OBJECTIVES: This study aimed to evaluate the efficacy of sacituzumab govitecan (SG) in patients with metastatic triple-negative breast cancer (mTNBC) in real-world settings.
METHODS: A systematic literature search was performed in publicly available databases using relevant search strings till December 2025. A supplementary open search was also run-on Google to identify any missed relevant articles. The studies were screened and the relevant data in it were extracted by three reviewers independently. The risk of bias of the included studies was assessed qualitatively using the ROBINS-I tool. The outcomes evaluated were overall response rate (ORR), complete response rate (CRR), overall survival (OS) and progression-free survival (PFS).
RESULTS: Seventeen studies reporting efficacy of SG in real-world settings were included. The sample size of the included studies ranged from 33 to 381 participants. The median age of the participants in the included studies was 55 (range: 48 - 61) years. This meta-analysis estimated an ORR of 35.97% (95% CI: 30.87% - 41.92%, I² = 66%, p-value = 0.00). The CRR estimated was 3.00% (95% CI: 1.36% - 6.63%, I² = 58%, p-value = 0.04). The median OS estimated was 10.43 months (95% CI: 9.43 - 11.43, I² = 74%, p-value = 0.00). The median PFS estimated was 4.66 months (95% CI: 4.30 - 5.02, I² = 48%, p-value = 0.02). The overall risk of bias was moderate in all the included studies.
CONCLUSIONS: The study findings are comparable to that observed in the Phase III ASCENT study which reported a median PFS of 4.8 months, median OS of 11.8 months, ORR of 31%, and CRR of 4% in pretreated mTNBC patients who received SG. This suggests that the efficacy observed in the real-world settings is similar to that reported in the Phase III ASCENT study.